Dizal Pharmaceuticals

688192 · SSE STAR Market

Public Market Listing

688192SSE STAR Market

SSE STAR Market primary exchange listing

Live quotes, historical charts, and market capitalization for Dizal Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Sunvozertinib(Zegfrovy)
Approved
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 1/2
EGFRSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
DZD6008Phase 1/2Non Small Cell Lung Cancer
Est. primary completion 2027-06 · NCT07070440 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Sunvozertinib · Zegfrovy + DZD6008Phase 1/2Non-Small Cell Lung Cancer
Est. primary completion 2028-06 · NCT07079475 · CT.gov ↗
What to watch
2029 (1)
September 2029 (1)
Sunvozertinib · ZegfrovyPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2029-09 · NCT07182682 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 September 2026Filing acceptedSunvozertinibAstraZeneca reports FDA acceptance of the first-line Zegfrovy sNDA (WU-KONG28)
US, FDA · AstraZeneca · Source ↗
27 May 2026Filing acceptedSunvozertinibChina CDE accepts sunvozertinib first-line application
CN, NMPA · Dizal · Source ↗
27 May 2026Priority reviewSunvozertinibChina CDE grants priority review to sunvozertinib first-line application
CN, NMPA · Dizal · Source ↗
21 March 2026Topline resultSunvozertinibWU-KONG28 Phase 3 meets primary endpoint
Dizal · Source ↗

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$112M$119M$42M$106Mreport ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$50M——$120Mreport ↗
2023-FY$13M——$159Mreport ↗